Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Omega Therapeutics (OMGA – Research Report), Rain Therapeutics (RAIN – Research Report) and Kinnate Biopharma (KNTE – Research Report).
Omega Therapeutics (OMGA)
Wedbush analyst Robert Driscoll maintained a Buy rating on Omega Therapeutics yesterday and set a price target of $12.00. The company’s shares closed last Friday at $1.70, close to its 52-week low of $1.30.
According to TipRanks.com, Driscoll has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Omega Therapeutics with a $12.00 average price target, representing a 622.9% upside. In a report issued on November 1, Piper Sandler also initiated coverage with a Buy rating on the stock with a $10.00 price target.
See today’s best-performing stocks on TipRanks >>
Rain Therapeutics (RAIN)
Mizuho Securities analyst Graig Suvannavejh maintained a Hold rating on Rain Therapeutics today and set a price target of $1.00. The company’s shares closed last Friday at $1.10, close to its 52-week low of $0.82.
According to TipRanks.com, Suvannavejh has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on Rain Therapeutics is a Hold with an average price target of $1.00, a -2.9% downside from current levels. In a report released today, Oppenheimer also maintained a Hold rating on the stock.
Kinnate Biopharma (KNTE)
In a report released yesterday, David Nierengarten from Wedbush maintained a Hold rating on Kinnate Biopharma, with a price target of $2.00. The company’s shares closed last Friday at $1.17, close to its 52-week low of $1.04.
According to TipRanks.com, Nierengarten is a 5-star analyst with an average return of
Kinnate Biopharma has an analyst consensus of Moderate Buy, with a price target consensus of $2.70, which is a 126.9% upside from current levels. In a report released today, Piper Sandler also assigned a Hold rating to the stock with a $4.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on OMGA:
- Omega Therapeutics reports Q3 EPS (40c), consensus (53c)
- Omega Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
- Omega presents new preclinical data on pre-transcriptional control of genes
- Omega Therapeutics Presents New Preclinical Data Demonstrating Pre-Transcriptional Modulation of Multiple CXCL Genes by a Single Epigenomic Controller
- Omega Therapeutics presents new preclinical data on OTX-2101
